NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Apnimed, Inc. (APMD) Stock Analysis

Apnimed, Inc. (APMD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

APMD

$18.90

+$0.39 (+2.11%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APMD with… →

APMD Key Statistics

As of Oct 21, 2026
Trading
Open
$18.75
Previous Close
$18.51
Day's Range
18.57–19.57
52-Week Range
16.12–35.29
Volume
295.42K
Valuation
Market Cap
$786.82M
P/E Ratio
2.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.83
EPS (ttm)Profit attributable to each share over the last twelve months.
7.22
Financials (FY)
Revenue (FY)
$38.47M+380.12%
Net Income (FY)
−$932.00K
Profit marginThe share of revenue left as profit after all costs and taxes.
142.10%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
41.63M
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
524.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Apnimed, Inc. (APMD) has a market capitalization of $786.82M.

In fiscal 2025, APMD reported revenue of $38.47M.

APMD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$38.47M−$932.00K−2.4%
2024$8.01M−$111.31M−1,389.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$38.47M$31.77M−$53.82M−$932.00K−2.4%
2024$8.01M$4.64M−$114.23M−$111.31M−1,389.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APMD Valuation vs Biotechnology Median

Median of 608 stocks
MetricAPMDBiotechnology medianvs median
P/E2.6216.600.2x the median
P/S ratio6.8313.3049% below
Profit margin142.10%−38.31%180.4 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Apnimed, Inc. (APMD) at $786.82M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 81 employees.

The most recent close on file for APMD is $18.90, dated October 21, 2026. That is +$0.39 (+2.11%) against the previous close. Over the past 52 weeks the price has ranged from $16.12 to $35.29. The latest close sits 17.25% above that 52-week low.

Financial Health

In fiscal 2025, Apnimed, Inc. reported revenue of $38.47M. Against the prior fiscal year total of $8.01M, that is a change of +380.12%. The same year closed with a net loss of $932.00K. Profit margin runs at 142.1%. That is 180.4 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 7.22.

Valuation Assessment

APMD trades at a trailing price-to-earnings ratio of 2.62. That is 0.2 times the Biotechnology median of 16.6. The price-to-sales ratio is 6.83. On price-to-sales that is 48.6% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Growth & Income

The record shows no dividend for APMD.

So far in 2026 the total return is −24.40%.

Peer Comparison

Apnimed, Inc. (APMD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apnimed, Inc. APMD $786.82M 2.6
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Apnimed, Inc. trades at a P/E of 2.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Apnimed, Inc.

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Visit website →